AtriCure, Inc (ATRC)

Etorro trading 970x250
AtriCure, Inc (ATRC) Logo

About AtriCure, Inc

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio. Address: 7555 Innovation Way, Mason, OH, United States, 45040

AtriCure, Inc News and around…

Latest news about AtriCure, Inc (ATRC) common stock and company :

AtriCure to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference
12 Nov, 2021 FinancialContent

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.

Atricure Insider Sold $325K In Company Stock
08 Nov, 2021 Yahoo! Finance

Mark A Collar, Director at Atricure (NASDAQ:ATRC), made a large insider sell on November 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Collar sold 4,000 shares of Atricure at a price of $80.91. The total transaction amounted to $323,640. Collar still owns a total of 82,607 shares of Atricure worth, $7,198,373. Atricure shares are trading up 0.0% at $87.14 at the time of this writing on Monday morning. Now

AtriCure, inc (ATRC) Q3 2021 Earnings Call Transcript
04 Nov, 2021 FinancialContent

ATRC earnings call for the period ending September 30, 2021.

AtriCure (ATRC) Tops Q3 Earnings and Revenue Estimates
03 Nov, 2021 Yahoo! Finance

AtriCure (ATRC) delivered earnings and revenue surprises of 739.39% and 2.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

AtriCure Reports Third Quarter 2021 Financial Results
03 Nov, 2021 FinancialContent

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2021 financial results.

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
03 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement ...

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct, 2021 FinancialContent

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly ...

Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
27 Oct, 2021 Yahoo! Finance

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AtriCure to Participate in Upcoming Investor Conferences
26 Oct, 2021 FinancialContent

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences.

Is AtriCure Inc. (ATRC) Going to Burn These Hedge Funds?
25 Oct, 2021 Yahoo! Finance

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

Analysts Forecast 20% Upside For XHE
22 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $151.10 per unit.

AtriCure to Announce Third Quarter 2021 Financial Results
05 Oct, 2021 FinancialContent

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release third quarter 2021 financial results on Wednesday, November 3, 2021.

As smaller-company stocks wobble, this investor is finding winners in overlooked places
01 Sep, 2021 FinancialContent

Amelia Weir of the Paradigm Select Fund doesn't get caught up in groupthink with holdings in the technology, industrial and health sectors.

AtriCure to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
31 Aug, 2021 FinancialContent

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 19th Annual Global Healthcare Conference.

Return on Capital Employed Insights for AtriCure
20 Aug, 2021 FinancialContent

After pulling data from Benzinga Pro it seems like during Q2, AtriCure's (NASDAQ:ATRC) reported sales totaled $71.38 million. Despite a ...

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
12 Aug, 2021 Yahoo! Finance

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

RSI Alert: AtriCure (ATRC) Now Oversold
11 Aug, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Analysts Forecast 11% Upside For The Holdings of PTH
10 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA Healthcare Momentum ETF (PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $192.62 per unit.

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Notable Thursday Option Activity: KKR, CENX, ATRC
05 Aug, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in KKR & CO Inc (KKR), where a total volume of 20,196 contracts has been traded thus far today, a contract volume which is representative of approximately 2.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 103.5% of KKR's average daily trading volume over the past month, of 2.0 million shares..

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021
05 Aug, 2021 FinancialContent

Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ:ROKU) from Equal-Weight to Overweight. In ...

AtriCure, inc (ATRC) Q2 2021 Earnings Call Transcript
05 Aug, 2021 FinancialContent

ATRC earnings call for the period ending June 30, 2021.

AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
04 Aug, 2021 Yahoo! Finance

AtriCure (ATRC) delivered earnings and revenue surprises of -9.09% and 15.91%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

AtriCure Reports Second Quarter 2021 Financial Results
04 Aug, 2021 FinancialContent

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results.

The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
03 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

AtriCure to Participate at the Canaccord 41st Annual Growth Conference
30 Jul, 2021 FinancialContent

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference.

The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
13 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
09 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
08 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

AtriCure to Announce Second Quarter 2021 Financial Results
07 Jul, 2021 FinancialContent

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release second quarter 2021 financial results on Wednesday, August 4, 2021.

AtriCure, Inc (ATRC) is a NASDAQ Common Stock listed in , ,

970x250